Tag: KDC-MN-072

Agomelatine (S 20098) is a naphthalenic analog of melatonin and the first clinically approved antidepressant whose mechanism of action does not rely on direct modulation of monoamine reuptake or degradation. Developed by Servier Laboratories and granted European marketing authorization in 2009 under the trade names Valdoxan and Thymanax, agomelatine acts through high-affinity agonism at the melatonin MT1 and MT2 G-protein-coupled receptors (Ki approximately 0.1 nanomolar) combined with neutral antagonism at the serotonin 5-HT2C receptor (Ki approximately 630 nanomolar), a pharmacological profile that is unique among marketed antidepressants and that produces a synergistic downstream effect on circadian rhythm resynchronization, frontocortical dopamine and norepinephrine release, hippocampal neurogenesis, and brain-derived neurotrophic factor (BDNF) expression. The compound does not bind serotonin transporters, norepinephrine transporters, dopamine transporters, or any of the receptor families (muscarinic, histaminergic, adrenergic, GABAergic, glutamatergic, opioid) that produce the common adverse-event signatures of the selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, and tricyclic antidepressant classes, and consequently exhibits a tolerability profile characterized by the absence of sexual dysfunction, weight gain, discontinuation syndrome, and serotonin syndrome risk that distinguishes it from essentially all other antidepressant classes.

Clinical efficacy in major depressive disorder has been established in multiple randomized, double-blind, placebo-controlled trials at the approved oral dose of 25 to 50 mg once daily at bedtime; pooled head-to-head analyses against fluoxetine, sertraline, venlafaxine, paroxetine, and escitalopram demonstrate broadly comparable antidepressant efficacy with superior tolerability and lower dropout rates. Relapse prevention has been demonstrated in a 24-week extension study with significantly lower cumulative relapse rate on agomelatine (24 percent) compared to placebo (50 percent). A separate clinical evidence base supports efficacy in generalized anxiety disorder, with randomized placebo-controlled trials demonstrating superiority on the Hamilton Anxiety Rating Scale and comparable efficacy to escitalopram with superior sleep restoration.

Pharmacokinetics are dominated by extensive hepatic first-pass metabolism through cytochrome P450 1A2 (CYP1A2, accounting for approximately 90 percent of clearance) and CYP2C9/CYP2C19 (approximately 10 percent), producing an oral bioavailability of approximately 1 percent despite greater than 80 percent gastrointestinal absorption, a plasma elimination half-life of 1 to 2 hours, and high inter-individual variability driven principally by CYP1A2 activity. The major metabolites (3-hydroxy-agomelatine, 7-desmethyl-agomelatine, and 3-hydroxy-7-desmethyl-agomelatine) are pharmacologically inactive and are renally eliminated after conjugation. CYP1A2 induction by tobacco smoking reduces plasma concentrations three- to fourfold; strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase exposure by up to 60-fold and are contraindicated in concurrent use.

The principal safety concern specific to agomelatine is dose-dependent hepatotoxicity, manifesting as transaminase elevation greater than three times the upper limit of normal in approximately 1.3 percent of patients at 25 mg daily and 2.5 percent at 50 mg daily. Serious hepatic reactions including cytolytic hepatitis and rare hepatic failure have been reported in postmarketing surveillance. Regulatory authorities require liver function testing before treatment initiation, at approximately 3, 6, 12, and 24 weeks of treatment, and at dose increase. Withdrawal of agomelatine leads to rapid normalization of transaminases in essentially all reported cases. The compound is contraindicated in patients with hepatic impairment.

This monograph reviews the chemistry, synthesis, and structural pharmacology of agomelatine; the dual-receptor mechanism in molecular and circadian detail; the comprehensive human pharmacokinetic record including CYP1A2 polymorphism and drug interactions; the clinical evidence base across major depressive disorder, generalized anxiety disorder, and sleep-related indications; the preclinical pharmacology including circadian, neurogenic, and anti-stress mechanisms; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the hepatotoxicity signal and broader adverse-event profile; and a comparative assessment of five alternative compounds (melatonin, ramelteon, tasimelteon, mirtazapine, vortioxetine) against agomelatine on five competency standards. The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antidepressant application; investigators should obtain analytical confirmation of identity and purity on every lot.